Form 4: Liquidia CEO Roger Jeffs Sells 75,000 Shares

Liquidia Corp CEO Roger Jeffs sold 75,000 shares of common stock over three days in May 2026 via a Rule 10b5-1 trading plan.

Summary

• CEO Roger Jeffs sold a total of 75,000 shares of Liquidia Corp common stock between May 5, 2026, and May 7, 2026.
• The sales were executed in three equal tranches of 25,000 shares each.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025.
• The shares were sold at volume-weighted average prices ranging from $40.10 to $42.09 per share.
• Following these transactions, the reporting person retains beneficial ownership of 1,348,095 shares held through Serendipity BioPharma LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were conducted through a pre-planned 10b5-1 program, which is a standard and transparent practice for executive liquidity.

Positives

• The sales were executed pursuant to a pre-established Rule 10b5-1 plan, which is a standard mechanism for executives to sell stock without triggering insider trading concerns.

Negatives

• The sale of 75,000 shares by the CEO represents a reduction in his direct economic exposure to the company's equity.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's near-term valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person has committed to providing full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are common in the biopharmaceutical sector, often used for diversification or tax planning rather than reflecting a change in fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to manage equity holdings while maintaining compliance with SEC regulations.

Related Party Transactions

• The reporting person holds shares through the Roger A. Jeffs Living Trust and Serendipity BioPharma LLC, where he serves as trustee and manager, respectively.

Stakeholder Impact

• Shareholders should note the reduction in the CEO's total beneficial ownership, though the systematic nature of the sales suggests planned liquidity rather than a reaction to specific company news.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Liquidia, LQDA, Insider Trading, CEO, Stock Sale, Rule 10b5-1